Regeneron Pharmaceuticals REGN Total Liabilities
Total Liabilities at other companies
Other financials
Where this comes from
Reported directly by Regeneron Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:Liabilities.
The official record: Regeneron Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Regeneron Pharmaceuticals's total liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Regeneron Pharmaceuticals's total liabilities?
- Regeneron Pharmaceuticals (REGN) reported total liabilities of $9.45B in Q1 2026.
- How has Regeneron Pharmaceuticals's total liabilities changed year-over-year?
- Regeneron Pharmaceuticals's total liabilities increased by 15.8% year-over-year, from $8.16B to $9.45B.
- What is the long-term trend for Regeneron Pharmaceuticals's total liabilities?
- Over 5 years (2020 to 2025), Regeneron Pharmaceuticals's total liabilities has grown at a 8.7% compound annual growth rate (CAGR), from $6.14B to $9.3B.
- What does total liabilities mean?
- The sum of all current and non-current obligations — everything the company owes to creditors, employees, governments, and other stakeholders.